Company / Operating Income
Corvus Pharmaceuticals, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$27.5M
FY2024
5-year range
-$43.8M / -$23.4M
FY2020-FY2024
Trend
-17.7%
vs FY2023
Sector context
#64 of 202
Health Care
What the data says
At -$28M, Corvus Pharmaceuticals, Inc.'s operating income ranks #64 of 202 in the Health Care sector. Improved from -$33M to -$28M over the past 2 years.
Based on SEC 10-K filings.
-$28M in FY2024.
Improved from -$33M to -$28M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#64 of 202 in Health CareTop 32% of 202This company -$27.5M Sector average $86.7M
▼
-131.8% below sector average
Key checks
Key Insights
- In FY2024, operating income decreased 17.7% year-over-year.
- Ranks #64 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2015.
- Lowest operating income in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$27.5M | -17.7% |
| FY2023 | -$23.4M | +28.1% |
| FY2022 | -$32.6M | +15.7% |
| FY2021 | -$38.6M | +11.7% |
| FY2020 | -$43.8M | +10.4% |
| FY2019 | -$48.9M | +0.7% |
| FY2018 | -$49.2M | +12.9% |
| FY2017 | -$56.5M | -52.9% |
| FY2016 | -$37.0M | -168.5% |
| FY2015 | -$13.8M | -8452.8% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026